Related topics: Industry Drivers
The US Food and Drug Administration (FDA) has approved Cervarix for vaccination against HPV and also granted a new indication to its rival Gardasil, which is now permitted for use in men.
GlaxoSmithKline’s Cervarix [human papillomavirus (HPV) bivalent (types 16 and 18) vaccine, recombinant] is now approved for use on women aged 10 to 25. Cervarix is designed to prevent cervical cancers associated with oncogenic HPV types 16 and 18.
On the same day Merck stated that Gardasil [human papillomavirus quadrivalent (Types 6, 11, 16, and 18) vaccine, recombinant] has been approved for preventing genital warts in men aged nine to 26.
Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
